Document:

Wells Fargo & Company - 8-K

Exhibit 4.1

[Face of Note]

 

Unless
this certificate is presented by an authorized representative of The Depository Trust Company, a New York corporation (“DTC”),
to the Company or its agent for registration of transfer, exchange or payment, and any certificate issued is registered in the
name of Cede & Co. or in such other name as requested by an authorized representative of DTC (and any payment is made to Cede
& Co. or such other entity as is requested by an authorized representative of DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF
FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL inasmuch as the registered owner hereof, Cede & Co., has an interest
herein.

	CUSIP NO. 95001D2P4	 	PRINCIPAL AMOUNT:  $____________
	REGISTERED NO. _________	 	 

 

 

WELLS FARGO
& COMPANY

 

MEDIUM-TERM
NOTE, SERIES T

 

Due Nine
Months or More From Date of Issue

 

Notes due
July 30, 2022

 

WELLS
FARGO & COMPANY, a corporation duly organized and existing under the laws of the State of Delaware (hereinafter called the
“Company,” which term includes any successor corporation under the Indenture hereinafter referred to), for
value received, hereby promises to pay to CEDE & Co., or registered assigns, the principal sum of ___________________________
($________) on July 30, 2022 (the “Stated Maturity Date”) and to pay interest thereon from July 30,
2018 or from the most recent Interest Payment Date to which interest has been paid or duly provided for semi-annually on each
January 30 and July 30, commencing January 30, 2019, and at Maturity (each, an “Interest Payment Date”),
at the rate per annum specified below until the principal hereof is paid or made available for payment. The interest so payable,
and punctually paid or duly provided for, on any Interest Payment Date will, as provided in the Indenture, be paid to the Person
in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on the Regular Record
Date for such interest next preceding such Interest Payment Date. The Regular Record Date for an Interest Payment Date shall be
one Business Day prior to such Interest Payment Date. If an Interest Payment Date is not a Business Day, interest on this Security
shall be payable on the next day that is a Business Day, with the same force and effect as if made on such Interest Payment Date,
and without any interest or other payment with respect to the delay. “Business Day” shall mean a day, other
than a Saturday or Sunday, that is neither a legal holiday nor a day on which banking institutions are authorized or required
by law or regulation to close in New York, New York.

 

Except
as described below for the first Interest Period, on each Interest Payment Date, interest will be paid for the period commencing
on and including the immediately preceding Interest Payment Date and ending on and including the day immediately preceding that
Interest Payment Date. This period is referred to as an “Interest Period.” The first Interest Period will

 

    	 

    	 

    

 

commence on
and include July 30, 2018 and end on and include January 29, 2019. Interest on this Security will be computed on the basis
of a 360-day year of twelve 30-day months.

 

The
interest rate on this Security that will apply during an Interest Period will be as follows:

 

	Commencing
July 30, 2018 and ending July 29, 2019
		

        3.00% per annum

	Commencing
July 30, 2019 and ending July 29, 2020
		

        3.25% per annum

	Commencing
July 30, 2020 and ending July 29, 2021
		

        3.50% per annum

	Commencing
July 30, 2021 and ending July 29, 2022
		

        4.00% per annum

 

Any
interest not punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Regular Record Date
and may either be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the
close of business on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof
shall be given to Holders of Securities of this series not less than 10 days prior to such Special Record Date, or be paid
at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Securities
of this series may be listed, and upon such notice as may be required by such exchange, all as more fully provided in the Indenture.

Payment
of interest on this Security will be made in immediately available funds at the office or agency of the Company maintained for
that purpose in the City of Minneapolis, Minnesota in such coin or currency of the United States of America as at the time of
payment is legal tender for payment of public and private debts; provided, however, that, at the option of the Company, payment
of interest may be paid by check mailed to the Person entitled thereto at such Person’s last address as it appears in the
Security Register or by wire transfer to such account as may have been designated by such Person. Payment of principal of and
interest on this Security at Maturity will be made against presentation of this Security at the office or agency of the Company
maintained for that purpose in the City of Minneapolis, Minnesota. Notwithstanding the foregoing, for so long as this Security
is a Global Security registered in the name of the Depositary, payments of principal and interest on this Security will be made
to the Depositary by wire transfer of immediately available funds.

This
Security is redeemable at the option of the Company, in whole but not in part, on any Optional Redemption Date at a Redemption
Price equal to 100% of the principal amount of this Security to be redeemed, plus any accrued but unpaid interest to, but excluding,
the Redemption Date. The “Optional Redemption Dates” are quarterly on the 30th day of each January,
April, July and October, commencing July 30, 2019 and ending April 30, 2022. Notice of any redemption will be mailed
at least 5 but not more than 30 days before the applicable Redemption Date to the Holder hereof. Unless the Company defaults in
the payment of the Redemption Price, on or after the Redemption Date, interest will cease to accrue on this Security or the portion
hereof called for redemption.

    	 	2	 

     

    

This
Security is not subject to repayment at the option of the Holder hereof prior to July 30, 2022. This Security is not entitled
to any sinking fund.

Reference
is hereby made to the further provisions of this Security set forth on the reverse hereof, which further provisions shall for
all purposes have the same effect as if set forth at this place.

Unless
the certificate of authentication hereon has been executed by the Trustee referred to on the reverse hereof by manual signature
or its duly authorized agent under the Indenture referred to on the reverse hereof by manual signature, this Security shall not
be entitled to any benefit under the Indenture or be valid or obligatory for any purpose.

 

 

[The
remainder of this page has been left intentionally blank]

 

    	 	3	 

     

    

 

IN
WITNESS WHEREOF, the Company has caused this instrument to be duly executed.

	DATED:	 	 	 

	 	WELLS FARGO & COMPANY
	 	 
	 	 
	 	 
	 	 
	 	By:	 	 
	 	 	 	 
	 	 	Its:	 	 
	 	 	 	 	 

 

	 	Attest:	 	 
	 	 	 	 
	 	 	Its:	 	 
	 	 	 
	 	 

 

TRUSTEE’S
CERTIFICATE OF

AUTHENTICATION

This is one
of the Securities of the 

series designated
therein described

in the within-mentioned
Indenture.

 

 

CITIBANK,
N.A.,

as
Trustee

 

	By:	 	 	 
	 	Authorized
Signature	 	 

 

OR

 

WELLS FARGO
BANK, N.A., 

as
Authenticating Agent for the Trustee 

 

	By:	 	 	 
	 	Authorized
Signature	 	 

 

 

    	 	4	 

     

    

 

[Reverse of
Note]

 

 

WELLS FARGO
& COMPANY

 

MEDIUM-TERM
NOTE, SERIES T

 

Due Nine
Months or More From Date of Issue

 

Notes due
July 30, 2022

 

This
Security is one of a duly authorized issue of securities of the Company (herein called the “Securities”), issued
and to be issued in one or more series under an indenture dated as of February 21, 2017, as amended or supplemented from
time to time (herein called the “Indenture”), between the Company and Citibank, N.A., as Trustee (herein called
the “Trustee,” which term includes any successor trustee under the Indenture), to which Indenture and all indentures
supplemental thereto reference is hereby made for a statement of the respective rights, limitations of rights, duties and immunities
thereunder of the Company, the Trustee and the Holders of the Securities, and of the terms upon which the Securities are, and
are to be, authenticated and delivered. This Security is one of the series of the Securities designated as Medium-Term Notes,
Series T, of the Company. The Securities of this series will bear interest at a fixed rate or a floating rate. The Securities
of this series may mature at different times, be redeemable at different times or not at all, be repayable at the option of the
Holder at different times or not at all and be denominated in different currencies.

The
Securities are issuable only in registered form without coupons and will be either (a) book-entry securities represented
by one or more Global Securities recorded in the book-entry system maintained by the Depositary or (b) certificated securities
issued to and registered in the names of, the beneficial owners or their nominees.

The
Company agrees, to the extent permitted by law, not to voluntarily claim the benefits of any laws concerning usurious rates of
interest against a Holder of this Security.

Modification
and Waivers 

The
Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations
of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by
the Company and the Trustee with the consent of the Holders of a majority in principal amount of the Securities at the time Outstanding
of all series to be affected, acting together as a class. The Indenture also contains provisions permitting the Holders of a majority
in principal amount of the Securities of all series at the time Outstanding affected by certain provisions of the Indenture, acting
together as a class, on behalf of the Holders of all Securities of such series, to waive compliance by the Company with those
provisions of the Indenture. Certain past defaults under the Indenture and their consequences may be waived under the Indenture
by the Holders of a majority in principal amount of the Securities of each series at the time Outstanding, on behalf of the Holders
of all Securities of such series. Any such consent or waiver by the Holder of this Security shall be conclusive and binding

    	 	5	 

     

    

upon
such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or
in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Security.

Defeasance

Section 403
and Article Fifteen of the Indenture and the provisions of clause (ii) of Section 401(1)(B) of the Indenture, relating
to defeasance at any time of (a) the entire indebtedness on this Security and (b) certain restrictive covenants, upon
compliance by the Company with certain conditions set forth therein, shall not apply to this Security. The remaining provisions
of Section 401 of the Indenture shall apply to this Security.

Authorized
Denominations

This
Security is issuable only in registered form without coupons in denominations of $1,000 or any amount in excess thereof which
is an integral multiple of $1,000.

Registration
of Transfer

Upon
due presentment for registration of transfer of this Security at the office or agency of the Company in the City of Minneapolis,
Minnesota, a new Security or Securities of this series, with the same terms as this Security, in authorized denominations for
an equal aggregate principal amount will be issued to the transferee in exchange herefor, as provided in the Indenture and subject
to the limitations provided therein and to the limitations described below, without charge except for any tax or other governmental
charge imposed in connection therewith.

This
Security is exchangeable for definitive Securities in registered form only if (x) the Depositary notifies the Company that
it is unwilling or unable to continue as Depositary for this Security or if at any time the Depositary ceases to be a clearing
agency registered under the Securities Exchange Act of 1934, as amended, and a successor depositary is not appointed within 90 days
after the Company receives such notice or becomes aware of such ineligibility, (y) the Company in its sole discretion determines
that this Security shall be exchangeable for definitive Securities in registered form and notifies the Trustee thereof or (z)
an Event of Default with respect to the Securities represented hereby has occurred and is continuing. If this Security is exchangeable
pursuant to the preceding sentence, it shall be exchangeable for definitive Securities in registered form, bearing interest at
the same rate, having the same date of issuance, Stated Maturity Date and other terms and of authorized denominations aggregating
a like amount. 

This
Security may not be transferred except as a whole by the Depositary to a nominee of the Depositary or by a nominee of the Depositary
to the Depositary or another nominee of the Depositary or by the Depositary or any such nominee to a successor of the Depositary
or a nominee of such successor. Except as provided above, owners of beneficial interests in this Global Security will not be entitled
to receive physical delivery of Securities in definitive form and will not be considered the Holders hereof for any purpose under
the Indenture.

Prior
to due presentment of this Security for registration of transfer, the Company, the Trustee and any agent of the Company or the
Trustee may treat the Person in whose name this

    	 	6	 

     

    

Security
is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither the Company, the Trustee
nor any such agent shall be affected by notice to the contrary.

Obligation
of the Company Absolute

No
reference herein to the Indenture and no provision of this Security or the Indenture shall alter or impair the obligation of the
Company, which is absolute and unconditional, to pay the principal of and interest on this Security at the times, place and rate,
and in the coin or currency, herein prescribed, except as otherwise provided in this Security.

No
Personal Recourse

No
recourse shall be had for the payment of the principal of or the interest on this Security, or for any claim based hereon, or
otherwise in respect hereof, or based on or in respect of the Indenture or any indenture supplemental thereto, against any incorporator,
stockholder, officer or director, as such, past, present or future, of the Company or any successor corporation, whether by virtue
of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise, all such liability
being, by the acceptance hereof and as part of the consideration for the issuance hereof, expressly waived and released.

Defined
Terms

All
terms used in this Security which are defined in the Indenture shall have the meanings assigned to them in the Indenture unless
otherwise defined in this Security.

Governing
Law

This
Security shall be governed by and construed in accordance with the law of the State of New York, without regard to principles
of conflicts of laws.

    	 	7	 

     

    

ABBREVIATIONS

 

 

The
following abbreviations, when used in the inscription on the face of this instrument, shall be construed as though they were written
out in full according to applicable laws or regulations:

 

TEN COM

--

as
tenants in common

 

TEN ENT

--

as
tenants by the entireties

 

JT TEN

--

as
joint tenants with right

of
survivorship and not

as
tenants in common

 

	UNIF GIFT MIN ACT --	 	Custodian	 	 
	 	(Cust)	 	(Minor)	 

 

 

Under Uniform
Gifts to Minors Act

 

	 	 	 
	(State)	 	 

 

Additional
abbreviations may also be used though not in the above list.

 

 

FOR
VALUE RECEIVED, the undersigned hereby sell(s) and transfer(s) unto

 

Please Insert
Social Security or

Other Identifying
Number of Assignee

 

	 	 	 

 

 

	 
	 
	 
	 
	 

 

(Please
print or type name and address including postal zip code of Assignee)

 

    	 	8	 

     

    

the
within Security of WELLS FARGO & COMPANY and does hereby irrevocably constitute and appoint __________________ attorney to
transfer the said Security on the books of the Company, with full power of substitution in the premises.

 

 

	Dated:	 	 	 

 

	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

 

NOTICE: The
signature to this assignment must correspond with the name as written upon the face of the within instrument in every particular,
without alteration or enlargement or any change whatever.

 

 

    	 	9TherapeuticsMD, Inc. - 10-Q

 

Exhibit 10.1

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS
ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 

EXECUTION VERSION

 

SOFTGEL COMMERCIAL SUPPLY AGREEMENT

(Estradiol softgel capsules) 

 

This Softgel Commercial
Supply Agreement (“Agreement”) is made as of this 20th day of April, 2016 (“Effective Date”),
by and between TherapeuticsMD, Inc., a Nevada corporation, with a place of business at 6800 Broken Sound Parkway NW, Third Floor,
Boca Raton, Florida 33487 (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company,
having a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873 (“Catalent”).

 

RECITALS

A.       

Client is a company
that develops, markets and sells pharmaceutical products;

B.       

Catalent is a leading
provider of advanced technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and
consumer healthcare companies;

C.       

Client and Catalent
have entered into the Master Development and Clinical Supply Agreement dated as of December 4, 2015 (the “Development
Agreement”); and

D.       

Client desires to engage
Catalent to provide certain services to Client in connection with the processing of Client’s Product, and Catalent desires
to provide such services, all pursuant to the terms and conditions set forth in this Agreement.

THEREFORE,
in consideration of the mutual covenants, terms and conditions set forth below, the parties agree as follows:

ARTICLE 1

DEFINITIONS

The following terms have the following
meanings in this Agreement:

1.1       

“Acknowledgement”
has the meaning set forth in Section 4.3.

1.2       

“Affiliate(s)”
means, with respect to Client or any third party, any corporation, firm, partnership or other entity that controls, is controlled
by or is under common control with such entity; and with respect to Catalent, Catalent Pharma Solutions, Inc. and any corporation,
firm, partnership or other entity controlled by it. For the purposes of this definition, “control” means the
ownership of at least 50% of the voting share capital of an entity or any other comparable equity or ownership interest or possession
of the right to control the management and policies of such entity.

1.3       

“Agreement”
has the meaning set forth in the introductory paragraph, and includes all its Attachments and other appendices agreed to by the
parties (all of which are incorporated herein by reference) and any amendments to any of the foregoing made as provided herein
or therein.

    	 		 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

1.4       

“API”
means the generic compound Estradiol, as further described in the Specifications that has been released by Client and provided
to Catalent, along with a certificate of analysis, as provided in this Agreement.

1.5       

“Applicable
Laws” means, with respect to Client, all laws, ordinances, rules and regulations of each jurisdiction in which API or
Product is produced, marketed, distributed, used or sold; and with respect to Catalent, all laws, treaties, or ordinances, rules,
regulations, cGMP, guidances, interpretations, authorizations, judgments, directives, injunctions, or orders of any court of any
international, national, regional, local, or other governmental body, agency, authority, or court, or arbitrator, that has jurisdiction
over the location where Catalent performs services under this Agreement (and applicable cGMP), including, but not limited to, the
Federal Food, Drug and Cosmetic Act and Good Laboratory Practices, in each of the foregoing cases as in effect from time-to-time.

1.6       

“Batch”
means a defined quantity of Product that has been or is being Processed in accordance with the Specifications.

1.7       

“Catalent”
has the meaning set forth in the introductory paragraph, or any successor or permitted assign. Catalent shall have the right to
cause any of its Affiliates, upon prior written notice to and approval from Client, to perform any of its obligations hereunder,
and Client upon its prior approval of the use of the Affiliate, shall accept such performance as if it were performance by Catalent,
but Catalent shall remain jointly and severally liable for the performance by any of its Affiliates under this Agreement.

1.8       

“Catalent
Defective Processing” has the meaning set forth in Section 5.2.

1.9       

“Catalent
Indemnitees” has the meaning set forth in Section 13.2.

1.10       

“Catalent
IP” has the meaning set forth in the Development Agreement.

1.11       

“cGMP”
means current Good Manufacturing Practices promulgated by the Regulatory Authorities in the jurisdictions included in Applicable
Laws (as applicable to Client and Catalent respectively). In the United States, this includes 21 C.F.R. Parts 210 and 211, as amended
together with pertinent guidelines and guidance documents; in the European Union, this includes 2003/94/EEC Directive (as supplemented
by Volume 4 of EudraLex published by the European Commission), as amended, if and as implemented in the relevant constituent country,
together with pertinent guidelines and guidance documents, in Japan (this includes the guidelines of good manufacturing control
and quality control based on the requirements of the Pharmaceutical Affairs law of Japan as implemented in April of 2005), and
in Canada (including the Food and Drugs Act, pertinent rules and regulations promulgated by Health Canada including Part C, Division
2 of the Food and Drugs Regulations and the Good Manufacturing Practices (GMP) Guidelines – 2009 Edition, Version 2).

1.12       

“Client”
has the meaning set forth in the introductory paragraph, or any successor or permitted assign.

1.13       

“Client
Indemnitees” has the meaning set forth in Section 13.1.

1.14       

“Client
IP” has the meaning set forth in the Development Agreement.

1.15       

“Client-supplied
Materials” means any materials to be supplied by or on behalf of Client to Catalent for Processing, as provided in Attachment
A, including API and reference standards.

1.16       

“Commencement
Date” means the date of first commercial sale by Client following approval by a Regulatory Authority of Catalent as a
manufacturer of the Product. Client shall notify Catalent in writing promptly following such first commercial sale.

1.17       

“Confidential
Information” has the meaning set forth in Section 10.1.

1.18       

“Contract
Year” means each consecutive 12 month period beginning on the Commencement Date or anniversary thereof, as applicable.

    	 	2	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

1.19       

“Defective
Product” has the meaning set forth in Section 5.2.

1.20       

“Development
Agreement” has the meaning set forth in Recital C.

1.21       

“Development
Batch” has the meaning set forth in the Development Agreement.

1.22       

“Discloser”
has the meaning set forth in Section 10.1.

1.23       

“Effective
Date” has the meaning set forth in the introductory paragraph.

1.24       

“Exception
Notice” has the meaning set forth in Section 5.2.

1.25       

“Facility”
means Catalent’s facility located in St. Petersburg, Florida or Morrisville, North Carolina; or such other facility as agreed
by the parties in writing.

1.26       

“Firm Commitment”
has the meaning set forth in Section 4.2.

1.27       

“Generic
Product” has the meaning set forth in Section 11.5.

1.28       

“Invention”
has the meaning set forth in Article 11.

1.29       

“Losses”
has the meaning set forth in Section 13.1.

1.30       

“Marks”
means trademarks, trade names, service marks, logos and symbols.

1.31       

“Minimum
Requirement” has the meaning set forth in Section 4.1.

1.32       

“Process”
or “Processing” means the compounding, filling, encapsulating, producing, testing and bulk packaging (but not
secondary or retail packaging) of Client-supplied Materials and Raw Materials into Product by Catalent, in accordance with the
Specifications and under the terms of this Agreement.

1.33       

“Processing
Date” means the day on which the first step of physical Processing is scheduled to occur, as identified in an Acknowledgement.

1.34       

“Process
Know-How” means all know-how provided by Client to Catalent and, subject to the exclusions in the next sentence, certain
know-how to the extent it relates to the processing, manufacture, quality control, formulation, filling, finishing, testing and
packaging of a Product, whether in bulk or final form, and regardless of container, including, without limitation, analytical tests
methods for in-process and final Product, copies of manufacturing records, formulation recipes, designs and drawings (limited to
ink print design, and capsule color, shape, and design), and formulae, used in the delivery of Processing for a Product to the
extent it is in the possession, or under the control, of Catalent, its Affiliates and their respective subcontractors; “Process
Know-How” does not include any of the following: (i) Catalent IP, and (ii) the proprietary process information contained
in the drug master file, including without limitation, the gelatin master batch record, the gelatin conversion section of the master
batch record, the encapsulation set up page, and processing aids (lubricants and wash solution).

    	 	3	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

1.35       

“Process
Know-How Transfer” means the commercially reasonable efforts of the parties undertaken pursuant to the Process Know-How
Transfer Plan to transfer copies of all Process Know-How (together with relevant books and records) and the “Standards”
(defined below) in Catalent’s possession, to Client as set forth in greater detail in the Process Know-How Transfer Plan.
Catalent shall only be obligated to use its commercially reasonable efforts in the implementation of the Process Know-How Transfer
Plan, and in no case shall Catalent personnel visit the site of Client or any third party manufacturer of softgels, as the case
may be. For the avoidance of doubt, the foregoing prohibition shall not be construed as a basis for Catalent refusing to assist
in the transfer of analytical methods to an independent laboratory, including a visit by Catalent personnel to such site to assist
in method transfer, if, and only as, reasonably necessary, and at Client’s cost and expense. As used herein “Standards”
means data, information, or samples of validated or Catalent manufactured or partially manufactured Product or other indicia measured
at various points during Processing, to the extent Catalent possesses such data, information, or samples. “Standards”
does not include any of the following: (i) Catalent IP, and (ii) the proprietary process information contained in the drug master
file, including without limitation, the gelatin master batch record, the gelatin conversion section of the master batch record,
the encapsulation set up page, and processing aids (lubricants and wash solution).

1.36       

“Process
Know-How Transfer Plan” means that plan addressing orderly Process Know-How Transfer, to be prepared in writing and reasonably
agreed to by the parties within the sixty (60) day period following notice from Client to Catalent of its intention to commence
Process Know-How Transfer.

 1.37

“Product” means
the bulk pharmaceutical product containing the API, as more specifically described in the Specifications.

1.38       

“Product
Maintenance Services” has the meaning set forth in Section 2.2.

1.39       

“Purchase
Order” has the meaning set forth in Section 4.3.

1.40       

“Quality
Agreement” has the meaning set forth in Section 9.6.

1.41       

“Raw Materials”
means all raw materials, supplies, components and packaging necessary to manufacture and ship Product in accordance with the Specifications,
but excluding Client-supplied Materials.

1.42       

“Recall”
has the meaning set forth in Section 9.5.

1.43       

“Recipient”
has the meaning set forth in Section 10.1.

1.44       

“Regulatory
Approval” means any approvals, permits, product and/or establishment licenses, registrations or authorizations, including
approvals pursuant to U.S. Investigational New Drug Applications, New Drug Applications and Abbreviated New Drug Applications,
as applicable, of any Regulatory Authorities that are necessary or advisable in connection with the development, manufacture, testing,
use, storage, exportation, importation, transport, promotion, marketing, distribution or sale of API or Product in the Territory.

1.45       

“Regulatory
Authority” means the international, federal, state or local governmental or regulatory bodies, agencies, departments,
bureaus, courts or other entities in the Territory that are responsible for (A) the regulation (including pricing) of any aspect
of pharmaceutical or medicinal products intended for human use including, but not limited to, their manufacture, handling and storage,
or (B) health, safety or environmental matters generally. In the United States, this includes the United States Food and Drug Administration.

1.46       

“Representatives”
of an entity mean such entity’s duly-authorized officers, directors, employees, agents, accountants, attorneys or other professional
advisors.

1.47       

“Review
Period” has the meaning set forth in Section 5.2.

1.48       

“Rolling
Forecast” has the meaning set forth in Section 4.2.

    	 	4	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

1.49       

“Sample”
has the meaning set forth in Section 5.1.

1.50       

“Softgel
Technology” means Catalent’s proprietary technology, whether or not patented or patentable, for the manufacture
of softgels for various uses, including the oral administration of pharmaceutically active ingredients (including health and nutritional
substances). The Softgel Technology includes proprietary know how relating to (A) the development of fill and shell formulations,
(B) the design and use of the encapsulation process to enhance stability, solubility, bioavailability and manufacturability of
active ingredient chemical entities in softgels, (C) the selection and preparation of solvents, vehicles, excipients, surfactants,
stabilizers, gelatin and gelatin substitutes, plasticizers and other components of the liquid fill and the shell and (D) certain
encapsulation, drying and related manufacturing techniques and machinery for making experimental, clinical, or commercial quantities
of softgels. For clarity, Softgel Technology does not encompass any technology or information provided by Client to Catalent, including,
but not limited to, the formulation of the Product.

1.51       

“Specifications”
means the procedures, requirements, standards, quality control testing and other data and the scope of services as set forth in
Attachment A, as modified from time to time in accordance with Article 8.

1.52       

“Term”
has the meaning set forth in Section 16.1.

1.53       

“Territory”
means the United States of America, and any other country that the parties agree in writing to add to this definition of Territory
in an amendment to this Agreement, except shall not include countries that are targeted by the comprehensive sanctions, restrictions
or embargoes administered by the United Nations, European Union, United Kingdom, or the United States. Catalent shall not be obliged
to Process Products for sale in any of such countries if it is prevented from doing so, or would be required to obtain or apply
for special permission to do so, due to any restrictions (such as embargoes) imposed on it by any governmental authorities, including
without limitation, those imposed by the U.S. Office of Foreign Asset Control.

1.54       

“Unit Pricing”
has the meaning set forth in Section 7.1(A).

1.55       

“Vendor”
has the meaning set forth in Section 3.2(B).

ARTICLE 2

PROCESSING & RELATED SERVICES

2.1       

Supply and Purchase
of Product. Catalent shall Process Product in accordance with the Specifications, Applicable Laws and the terms and conditions
of this Agreement.

2.2       

Product Maintenance
Services. Client will receive the following product maintenance services (the “Product Maintenance Services”):
one annual audit (as further described in Section 9.5); regulatory audits (as further described in Section
9.4); one annual Product review (within the meaning of 21 CFR § 221.180); drug master file updates for the Territory, if applicable;
access to document library over and above the Quality Agreement, including additional copies of Batch paperwork or other Batch
documentation; assistance in preparing Regulatory Approvals; Product document and sample storage relating to cGMP requirements;
vendor re-qualification; and maintenance, updates and storage of master batch records and audit reports. For avoidance of doubt,
the following services and items are not included in Product Maintenance Services: technology transfer; analytical work; stability;
and process rework.

2.3       

Other Related
Services. Catalent shall provide such Product-related services, other than Processing or Product Maintenance Services, as agreed
to in writing by the parties from time to time. Such writing shall include the scope and fees for any such services and be appended
to this Agreement. The terms and conditions of this Agreement shall govern and apply to such services.

2.4       

Validation Services.
Catalent shall Process validation Batches and perform validation services at prices to be agreed in writing between the parties.

    	 	5	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

ARTICLE 3

MATERIALS

3.1       

Client-supplied
Materials.

A.       

Client shall supply
to Catalent for Processing, at Client’s cost, all Client-supplied Materials, in quantities sufficient to meet Client’s
requirements for Product. Client shall deliver such items and associated certificates of analysis to the Facility no later than
60 days (but not earlier than 90 days, unless agreed to by the Parties or accepted by Catalent) before the Processing Date. Client’s
failure to fulfill the foregoing obligations in this Section 3.1 shall not by itself give rise to a cause of action in Catalent
or a right by it to terminate this Agreement. Client shall be responsible at its expense for securing any necessary DEA, export
or import, similar clearances, permits or certifications required in respect of such supply. Catalent shall use such items solely
for Processing. Prior to delivery of any such items, Client shall provide to Catalent a copy of all associated material safety
data sheets, safe handling instructions and health and environmental information and any Regulatory certifications or authorizations
that may be required under Applicable Laws relating to the API and Product, and shall promptly provide any updates thereto.

B.       

Following receipt of
Client-supplied Materials, Catalent shall inspect such items employing such measures as are set forth in the Specifications. Catalent
will receive, handle, store and use all Client-supplied Materials in compliance with all Applicable Laws and labeled storage requirements,
or lacking labeled storage requirement, the written instructions of Client, as agreed to by Catalent, such agreement not to be
unreasonably withheld. Unless otherwise expressly required by the Specifications, Catalent shall have no obligation to test such
items to confirm that they meet the associated specifications or certificate of analysis or otherwise; but in the event that Catalent
detects a nonconformity with Specifications, Catalent shall give Client prompt notice of such nonconformity. Catalent shall not
be liable for any defects in Client-supplied Materials, or in Product resulting from defective Client-supplied Materials, unless
Catalent failed to properly perform the foregoing obligations. Catalent shall follow Client’s reasonable written instructions
in respect of return or disposal of defective Client-supplied Materials, at Client’s cost.

C.       

Client shall retain
title to Client-supplied Materials at all times and shall bear the risk of loss thereof, except for losses to the extent due to
the negligent acts or omissions of Catalent or Catalent’s failure to follow storage and handling requirements or mutually
agreed to written instructions of Client, in each case, subject to Article 14.

3.2       

Raw Materials.

A.       

Catalent shall be responsible
for procuring, inspecting and releasing adequate Raw Materials as necessary to meet the Firm Commitment, unless otherwise agreed
to by the parties in writing. Catalent shall not be liable for any delay in delivery of Product if (i) Catalent is unable to obtain,
in a timely manner, a particular Raw Material necessary for Processing and (ii) Catalent placed orders for such Raw Materials promptly
following receipt of Client’s Firm Commitment. In the event that any Raw Material becomes subject to purchase lead time beyond
the Firm Commitment time frame, the parties will negotiate in good faith an appropriate amendment to this Agreement, including
Section 4.2.

B.       

In certain instances,
Client may require a specific supplier, manufacturer or vendor (“Vendor”) to be used for Raw Material. In such
an event occurring after the Effective Date, (i) such Vendor will be identified in the Specifications and (ii) the Raw Materials
from such Vendor shall be deemed Client-supplied Materials for purposes of this Agreement. If the cost of the Raw Material from
any such Vendor is greater than Catalent’s costs for the same raw material of equal quality from other vendors, Catalent
shall add the difference between Catalent’s cost of the Raw Material and the Vendor’s cost of the Raw Material to the
Unit Pricing. Client will be responsible for all costs associated with qualification of any Vendor specifically required to be
used upon written instruction from Client, which Vendor has not been previously qualified by Catalent.

C.       

In the event of (i)
a Specification change for any reason, (ii) obsolescence of any Raw Material or (iii) termination or expiration of this Agreement,
Client shall bear the cost of any unused Raw Materials (including packaging), so long as Catalent purchased
such Raw Materials in quantities consistent with Client’s most recent Firm Commitment and the vendor’s minimum purchase
obligations. Such Raw Material shall be the property of Client upon payment therefor.

    	 	6	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

3.3       

Artwork and Labeling.
Client shall provide or approve, prior to the procurement of applicable Raw Material, all artwork, advertising and labeling information
necessary for Processing, if any. Such artwork, advertising and labeling information is and shall remain the exclusive property
of Client, and Client shall be solely responsible for the content thereof. Such artwork, advertising and labeling information or
any reproduction thereof may not be used by Catalent in any manner other than performing its obligations hereunder.

ARTICLE 4

MINIMUM COMMITMENT, PURCHASE ORDERS
& FORECASTS

4.1       

Minimum Requirement.
During each Contract Year, Client shall purchase the minimum number of units of Product set forth on Attachment B (“Minimum
Requirement”). If Client does not purchase such Minimum Requirement during any Contract Year, then within [***] days
after the end of such Contract Year, Client shall pay Catalent [***] of difference between (A) the total amount Client would have
paid to Catalent if the Minimum Requirement had been fulfilled for the Product and (B) the sum of all purchases of Product from
Catalent during such Contract Year. For the avoidance of doubt, validation Batches which are commercialized by Client shall count
towards satisfaction of the Minimum Requirement in the first Contract Year.

4.2       

Forecast.
On or before the [***] of each calendar month, beginning at least [***] prior to the anticipated Commencement Date, Client shall
furnish to Catalent a written [***] rolling forecast of the quantities of Product that Client intends to order from Catalent during
such period (“Rolling Forecast”); provided, that the quantities forecasted to be purchased in any rolling
[***] period commencing on the [***] of the Commencement Date shall not be less than [***] of the Minimum Requirement for the relevant
Contract Year. The first [***] of each such Rolling Forecast shall constitute a binding order for the quantities of Product specified
therein (“Firm Commitment”) and the following [***] of the Rolling Forecast shall be non-binding, good faith
estimates.

4.3       

Purchase Orders.

A.       

From time to time as
provided in this Section 4.3(A), Client shall submit to Catalent a binding, non-cancelable purchase order for Product specifying
the number of Batches to be Processed, the Batch size (to the extent the Specifications permit Batches of different sizes) and
the requested delivery date for each Batch (“Purchase Order”); provided, that no Purchase Order may be
for less than [***]. Concurrently with the submission of each Rolling Forecast, Client shall submit a Purchase Order for the Firm
Commitment. Purchase Orders for quantities of Product in excess of the Firm Commitment shall be submitted by Client at least [***]
days in advance of the delivery date requested in the Purchase Order.

B.       

Promptly following
receipt of a Purchase Order, Catalent shall issue a written acknowledgement (“Acknowledgement”) that it accepts
or rejects such Purchase Order. Each acceptance Acknowledgement shall either confirm the delivery date set forth in the Purchase
Order or set forth a reasonable alternative delivery date, and shall include the Processing Date. Catalent may reject any Purchase
Order in excess of the Firm Commitment or otherwise not given in accordance with this Agreement; provided, however, Catalent shall
accept any Purchase Order that meets the requirements of this Agreement if Client is not in arrears in paying amounts due and payable
under this Agreement.

C.       

Notwithstanding Section
4.3(B), Catalent shall use commercially reasonable efforts to supply Client with quantities of Product which are up to [***] in
excess of the quantities specified in the Firm Commitment, subject to Catalent’s other supply commitments and manufacturing,
packaging and equipment capacity.

D.       

In the event of a conflict
between the terms of any Purchase Order or Acknowledgement and this Agreement, the terms of this Agreement shall control.

4.4       

Catalent’s
Cancellation of Purchase Orders. Notwithstanding Section 4.5, Catalent reserves the right to cancel all, or any part of, a
Purchase Order upon written notice to Client, and Catalent shall have no further obligations or liability with respect to such
Purchase Order, if Client refuses or fails to timely supply conforming Client-supplied Materials in accordance with Section 3.1.
Any such cancellation of Purchase Orders shall not constitute a breach of this Agreement by Catalent nor shall it absolve Client
of its obligation in respect of the Minimum Requirement. Catalent shall use reasonable efforts to re-schedule Processing reflected
on such Purchase Order promptly after conforming Client-supplied Materials are delivered to Catalent.

    	 	7	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

4.5       

Client’s
Modification or Cancellation of Purchase Orders.

A.       

Client may modify the
delivery date or quantity of Product in a Purchase Order only by submitting a written change order to Catalent at least [***] business
days in advance of the earliest Processing Date covered by such change order. Such change order shall be effective and binding
against Catalent only upon the written approval of Catalent, and notwithstanding the foregoing, Client shall remain responsible
for the Firm Commitment.

B.       

Notwithstanding any
amounts due to Catalent under Section 4.4 or Section 4.1, if Client fails to place Purchase Orders sufficient to satisfy the Firm
Commitment, Client shall pay to Catalent the Unit Pricing for all Units that would have been Processed if Client has placed Purchase
Orders sufficient to satisfy the Firm Commitment and Catalent shall Process and deliver such quantity of Product as if Purchase
Orders sufficient to satisfy the Firm Commitment had been placed.

C.       

Neither changes to
nor postponement of any Batch of Product, nor the payment of the fees described in this Section 4.5, will reduce or in any way
effect Client’s Minimum Requirement obligations set forth in Section 4.1; provided, however, any payment pursuant to this
Section 4.5 shall be applied towards the Minimum Requirement.

4.6       

Unplanned Delay
or Elimination of Processing. Catalent shall use commercially reasonable efforts to meet the Purchase Orders, subject to the
terms and conditions of this Agreement. Catalent shall provide Client with as much advance notice as practicable if Catalent determines
that any Processing will be delayed or eliminated for any reason. Any delay in Processing by Catalent in excess of [***], but less
than [***], days shall result in a proportional reduction of the Minimum Requirement pertaining to the then-current Contract Year,
based on the actual number of days of delay until normal, orderly Processing re-commences. Any delay in Processing subsisting for
a continuous period of [***] days, or the elimination of Processing representing in excess of [***] of the Minimum Requirement
for the Contract Year in which the relevant Purchase Orders were submitted shall result in an elimination of the Minimum Requirement
for the balance of such Contract Year, so long as such delay or elimination was not attributable to an act or omission of Client.

4.7       

Observation of
Processing. In addition to Client’s audit right pursuant to Section 9.4, Client may send up to 2 Representatives to the
Facility to observe Processing for a maximum of 10 days per Contract Year (unless otherwise agreed by Catalent in writing), upon
at least 10 business days’ prior notice, at reasonable times during regular business hours. The foregoing limitations shall
not apply to time spent by Client Representatives on site at the Facility to participate in or witness research and development
activities or to witness Processing of validation Batches of Product. Such Representatives shall abide by all Catalent safety rules
and other applicable employee policies and procedures, and Client shall be responsible for such compliance. Client shall indemnify
and hold harmless Catalent for any action, omission or other activity of such Representatives while on Catalent’s premises.
Client’s Representatives who are not employees of Client shall be required to sign Catalent’s standard visitor confidentiality
agreement prior to being allowed access to the Facility.

ARTICLE 5

TESTING; RELEASE

5.1       

Batch Release.
After Catalent completes Processing of a Batch, Catalent shall also provide Client or its designee with Catalent’s certificate
of analysis and certificate of compliance for such Batch. Issuance of a certificate of analysis and a certificate of compliance
by Catalent constitutes release of the Batch by Catalent to Client. Client shall be responsible for final release of Product to
the market.

    	 	8	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

5.2       

Testing; Rejection.
No later than [***] days after receipt of the Batch (“Review Period”), Client or its designee shall notify Catalent
whether the Batch conforms to Specifications. Upon receipt of notice from Client that a Batch meets Specifications, or upon failure
of Client to respond by the end of the Review Period, the Batch shall be deemed accepted by Client and Client shall have no right
to reject such Batch other than for defects which existed at the time of delivery and were not discovered or discoverable in the
exercise of reasonable care (“Latent Defects”). For the avoidance of doubt, (i) Batches failing to meet Specifications
at the time of delivery due to Latent Defects may be rejected, if at all, only upon notice to Catalent within [***] days following
the date on which such Latent Defect was discovered or should have been discovered in the exercise of reasonable care and (ii)
in no event may Client reject Product after such Product’s expiration date. If Client or its designee timely notifies Catalent
in writing (an “Exception Notice”) that a Batch does not conform to the Specifications or otherwise does not
meet the warranty set forth in Section 12.1(A), whether due to a Latent Defect or otherwise (“Defective Product”),
and provides a sample of the alleged Defective Product, Catalent shall conduct an appropriate investigation in its discretion to
determine whether or not it agrees with Client that Product is Defective Product and to determine the cause of any nonconformity.
If Catalent agrees that Product is Defective Product and determines that the cause of nonconformity is attributable to Catalent’s
failure to perform the Processing in accordance with the Specifications (“Catalent Defective Processing”), then
Section 5.4 shall apply. For avoidance of doubt, where the cause of nonconformity cannot be determined or assigned, it shall be
deemed not Catalent Defective Processing.

5.3       

Discrepant Results.
If the parties disagree as to whether Product is Defective Product and/or whether the cause of the nonconformity is Catalent Defective
Processing, and this is not resolved within 30 days of the Exception Notice date, the parties shall cause a mutually acceptable
independent third party to review records, test data and to perform comparative tests and/or analyses on samples of the alleged
Defective Product and its components, including Client-supplied Materials. The independent party’s results as to whether
or not Product is Defective Product and the cause of any nonconformity shall be final and binding. Unless otherwise agreed to by
the parties in writing, the costs associated with such testing and review shall be borne by Catalent if Product is Defective Product
attributable to Catalent Defective Processing, and by Client in all other circumstances. Client will be apprised in writing of
all Defective Product investigations executed by Catalent on Client’s materials/products, including Product and Client-supplied
Materials, as well as final investigation outcome and conclusion(s).

5.4       

Defective Processing.
Catalent shall, at Client’s option, either (A) replace at its cost another Batch of Product (as a replacement for any Batch
of Defective Product attributable to Catalent Defective Processing) using Client-supplied Materials provided at Client’s
cost or (B) credit any payments made by Client for such Batch. THE OBLIGATION OF CATALENT TO REPLACE CATALENT DEFECTIVE PROCESSING
IN ACCORDANCE WITH THE SPECIFICATIONS OR CREDIT PAYMENTS MADE BY CLIENT FOR DEFECTIVE PRODUCT ATTRIBUTABLE TO CATALENT DEFECTIVE
PROCESSING SHALL BE CLIENT’S SOLE AND EXCLUSIVE REMEDY UNDER THIS AGREEMENT FOR DEFECTIVE PRODUCT AND IS IN LIEU OF ANY OTHER
WARRANTY, EXPRESS OR IMPLIED.

ARTICLE 6

DELIVERY

6.1       

Delivery.
Catalent shall deliver Product ExWorks (Incoterms 2010) at the Facility promptly following Catalent’s release of Product;
provided, however, Catalent shall be responsible for loading the Product on the carrier’s vehicle using due care. Catalent
shall segregate and store all Product until tender of delivery. Title to Product shall transfer to Client upon such delivery. Client
shall qualify at least 2 carriers to ship Product and then designate the priority of such qualified carriers to Catalent.

6.2       

Storage Fees.
If Client fails to take delivery of any Product on any scheduled delivery date, Catalent shall store such Product until otherwise
instructed by Client and Client shall be invoiced on the first day of each month following such scheduled delivery for reasonable
administration and storage costs ([***] per pallet per month). Client will have at least [***] days after being notified that Product
is released to take delivery, and Catalent will provide reasonable notification of the scheduled dates when Product is expected
to be released. Such items shall be stored in compliance with requirements set forth in the Specification, or if no such storage
Specification exists for such item, Catalent shall store such items using due care taking into account the identity of such item.

6.3       

Subcontracting.
Catalent may utilize third parties to provide any part of the Processing only with the prior written approval of Client, provided
that the foregoing will not apply to generally available goods and services or to subcontracting to Catalent Affiliates. If Client
approves a subcontractor, then Catalent shall enter a written agreement with such subcontractor that enables Catalent to comply
with its obligations under this Agreement and places such subcontractors under obligations of confidentiality, non-use and intellectual
property ownership no less burdensome than those set forth herein and applicable to Catalent.  Catalent will oversee all services
performed by any subcontractor, and will be responsible for such services as if such services were performed by Catalent.
Catalent shall remain liable for the performance of its subcontractors under this Agreement. The use of subcontractors shall not
relieve Catalent of any responsibility under this Agreement.

    	 	9	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

ARTICLE 7

PAYMENTS

7.1

Fees. In consideration for
Catalent performing services hereunder:

A.       

Client shall pay Catalent
the unit pricing for Product set forth on Attachment B (“Unit Pricing”). Catalent shall submit an invoice
to Client for such fees upon tender of delivery of Product as provided in Section 6.1.

B.       

Client shall pay Catalent
the annual fees for Product Maintenance Services set forth on Attachment B. Catalent shall submit an invoice to Client for
such fees upon the Effective Date and upon each anniversary of the Effective Date during the Term.

C.       

Other Fees.
Client shall pay Catalent for all other fees and expenses of Catalent owing in accordance with the terms of this Agreement, including
pursuant to Sections 2.3, 4.1, 6.2 and 16.3. Catalent shall submit an invoice to Client for such fees as and when appropriate.

7.2       

Unit Pricing Increase.
The Unit Pricing shall be adjusted on an annual basis, effective on each July 1st (with the first price adjustment to be effective
on July 1, 2017), upon 60 days’ prior written notice from Catalent to Client, to reflect increases in labor, utilities and
overhead and shall be in an amount equal to the change in the Producer Price Index (“PPI”), "Pharmaceutical Preparation
Manufacturing” (Series ID: PCU325412325412), not seasonally adjusted, as published by the U.S. Department of Labor, Bureau
of Labor Statistics. The initial base period for comparison shall be the twelve (12) month period ending on the date most closely
preceding July 1, 2017, but which allows enough time for Catalent to provide to Client the notice required by this Section 7.2.
In addition, price increases for raw materials, and components shall be passed through to Client. For the avoidance of doubt, no
such annual increase shall exceed [***] in the aggregate for the PPI and raw materials and component
costs.

7.3       

Payment Terms.
Payment of all Catalent invoices shall be due 30 days after the date of invoice. No invoice shall be issued to Client for Processing
until the Batch so Processed has been delivered to Client pursuant to Section 6.1. Client shall make payment in U.S. dollars, and
otherwise as directed in the applicable invoice. If any payment is not received by Catalent by its due date, then Catalent may,
in addition to any other remedies available at equity or in law, charge interest on the outstanding sum from the due date (both
before and after any judgment) at 1.5% per month until paid in full (or, if less, the maximum amount permitted by Applicable Laws).

7.4       

Advance Payment.
Notwithstanding any other provision of this Agreement, if at any time Catalent reasonably determines that Client’s credit
has materially eroded as compared to its status as of the Effective Date, and Client is in arrears in paying amounts due under
this Agreement, Catalent may require payment in advance before performing any further services or making any further shipment of
Product. If Client shall fail, within a reasonable time, to make such payment in advance, or if Client shall fail to make any payment
when due, Catalent shall have the right, at its option, to suspend any further performance hereunder until such default is corrected,
without thereby releasing Client from its obligations under this Agreement.

    	 	10	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

7.5       

Taxes. All
taxes, duties and other amounts assessed (excluding tax based on net income and franchise taxes) on Client-supplied Materials,
services or Product prior to or upon provision or sale to Catalent or Client, as the case may be, are the responsibility of Client,
and Client shall reimburse Catalent for all such taxes, duties or other expenses paid by Catalent or such sums will be added to
invoices directed at Client, where applicable.

7.6       

Client and Third
Party Expenses. Except as may be expressly covered by Product Maintenance Service fees, Client shall be responsible for 100%
of its own and all third-party expenses associated with the development, Regulatory Approvals and commercialization of Product,
including regulatory filings and post-approval marketing studies. The preceding sentence shall not be construed in derogation of
Catalent’s obligations pursuant to Section 9.2 herein.

7.7       

Development Batches.
Development Batches produced after the Effective Date shall be deemed to have been produced under the Development Agreement. Client
will be responsible for the cost of such Development Batches, including those necessary to support the validation portion of Client’s
submissions for Regulatory Approvals, which fail to meet the Specifications as set forth in Section 4.1 of the Development Agreement.
Catalent and Client shall cooperate in good faith to resolve any problems causing the out-of-Specification Batch.

ARTICLE 8

CHANGES TO SPECIFICATIONS

8.1       

All Specifications
and any changes thereto agreed to by the parties from time to time shall be in writing, dated and signed by the parties. No change
in the Specifications shall be implemented by Catalent, whether requested by Client or requested or required by any Regulatory
Authority, until the parties have agreed in writing to such change, the implementation date of such change, and any increase or
decrease in costs, expenses or fees associated with such change (including any change to Unit Pricing). Catalent shall respond
promptly to any request made by Client for a change in the Specifications, and both parties shall use commercially reasonable,
good faith efforts to agree to the terms of such change in a timely manner. As soon as possible after a request is made for any
change in Specifications, Catalent shall notify Client of the costs associated with such change and shall provide such supporting
documentation as Client may reasonably require. Client shall pay all costs associated with such agreed upon changes. If there is
a conflict between the terms of this Agreement and the terms of the Specifications, this Agreement shall control. Catalent reserves
the right to postpone effecting changes to the Specifications until such time as the parties agree to and execute the required
written amendment.

ARTICLE 9

RECORDS; REGULATORY MATTERS

9.1       

Recordkeeping.
Catalent shall maintain complete and accurate Batch, laboratory data, reports and other technical records relating to Processing
in accordance with Catalent standard operating procedures. Such information shall be maintained for a period of at least 2 years
from the relevant finished Product expiration date or longer if required under Applicable Laws or the Quality Agreement. Catalent
will retain samples required by cGMP and such samples shall be stored at the Facility pursuant to Catalent’s standard operating
procedures. Prior to the destruction of any such Product specific items, Catalent shall notify Client of the impending destruction
and provide Client a reasonable opportunity to receive any or all such items.

    	 	11	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

9.2       

Regulatory Compliance.
Catalent shall obtain and maintain, at its cost and expense, all permits and licenses with respect to general Facility operations
required by any Regulatory Authority in the jurisdiction in which Catalent Processes Product. Client shall obtain and maintain,
at its cost and expense, all other Regulatory Approvals, authorizations and certificates, including those necessary for Catalent
to commence Processing. Client shall reimburse Catalent for any payments Catalent is required to make to any Regulatory Authority
pursuant to Applicable Laws resulting from Catalent’s formulation, development, manufacturing, processing, filling, packaging,
storing or testing of Client’s Product or Client-supplied Materials at the Facility (including without limitation any payments
or fees Catalent is required to make pursuant to the Generic Drug User Fee Amendments of 2012 (“GDUFA”) and pursuant
to Applicable Laws similar to GDUFA; provided, however, that on a Facility by Facility basis, in the event Catalent’s Facility
is referenced in a third party(ies) regulatory filing, the pertinent fee shall be apportioned and reduced accordingly between the
third party(ies) and Client for each year thereafter (e.g., in the event that Catalent is required to pay such fee as a result
of Client and a single third party, Client shall only be obligated to reimburse Catalent for [***]% of such fee payment). Catalent
and Client hereby acknowledge that as of the Effective Date, GDUFA does not apply to the Product or its Processing. Upon reasonable
written request, Client shall provide Catalent with a copy of applicable Regulatory Approvals required to distribute, market and
sell Product in the Territory. If Client is unable to provide such information, Catalent shall have no obligation to deliver Product
to Client, notwithstanding anything to the contrary in this Agreement. During the Term, Catalent will assist Client with all regulatory
matters relating to Processing and review the Common Technical Document pertaining to the Product and make such corrections as
are necessary to accurately reflect the Product, in each case at Client’s request and reasonable expense; provided, however,
Catalent shall review and correct such documents as they relate to Catalent activities at no charge to Client. In addition, Catalent
will maintain at Catalent’s expense, the relevant Drug Master File, including any updates thereto, and shall provide a letter
authorizing Client to reference Catalent Drug Master Files on file with the FDA and other regulatory authorities in connection
with the pursuit of Regulatory Approval for the Product. The parties intend and commit to cooperate to allow each party to satisfy
its obligations under Applicable Laws relating to Processing under this Agreement.

 9.3

Regulatory Communications.

A.       

Each party may communicate with any
governmental agency, including, but not limited to, governmental agencies responsible for granting regulatory approval for the
Products, regarding such Products if in the opinion of that party’s counsel, such communication is necessary to comply with
the terms of this Agreement or the requirements of any Applicable Law; provided, however, that unless in the reasonable opinion
of its counsel there is a legal prohibition against doing so, such party will permit the other party to review and take part in
any communications with the applicable agency, and to receive copies of all such communications from that agency.

B.       

Catalent will notify Client promptly
if Catalent receives any warning letters from or on behalf of a governmental agency directly related to the Product or systems
utilized in Processing the Product including, without limitation, any Form FDA-483. Catalent will provide Client copies of any
written communication from a governmental agency relating to a Client Product within three (3) business days of its receipt.

C.       

Catalent will promptly notify Client
upon receipt of a notice from a Regulatory Authority for an inspection of any Facility where the Processing is being performed
due to an issue related to the Product or a system used in the performance of such services, or, in the event of an unannounced
inspection, Catalent will provide such prior notice as is possible and permissible. If not prohibited by the Regulatory Authority,
Client will have the right to be present during such audit or inspection and any wrap-up meeting with such Regulatory Authority
as it applies to the Product. If Catalent receives any request by a Regulatory Authority with respect to the Product, including,
but not limited to, a notice of deficiency or FDA-483 that requires a written response regarding Client-supplied Materials, project,
or protocol, Catalent will provide a copy to Client of the deficiency notice within forty-eight (48) hours of Catalent’s
receipt of the notice. Catalent will provide Client a draft of the response prior to the response being submitted to the Regulatory
Authority so as to provide Client with reasonable time to review and comment on the response, which comments Catalent, in good
faith, will consider incorporating into the response.

    	 	12	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

9.4       

Governmental Inspections
and Requests. Catalent shall promptly advise Client if an authorized agent of any Regulatory Authority notifies Catalent that
it intends to or does visit a Facility or any other site for the purpose of reviewing the Processing or testing. Upon request,
Catalent shall provide Client with a copy of any report issued by such Regulatory Authority received by Catalent following such
visit, redacted as appropriate to protect any confidential information of Catalent and Catalent’s other customers. Client
acknowledges that it may not direct the manner in which Catalent fulfills its obligations to permit inspection by and to communicate
with Regulatory Authorities, but such acknowledgement shall not be construed to vitiate Catalent’s obligations to Client
pursuant to this Agreement. Client shall reimburse Catalent for all reasonable and documented costs, at a rate of [***] per hour,
associated with inspections by Regulatory Authorities specifically concerning the Product, such as the pre-approval inspection.
Client will not be required to pay costs to mitigate any deficiencies cited in a Form 483 or Catalent’s Facility deficiencies.
Such documentation will include a description of the activities and time expended for such inspections.

9.5       

Client Facility
Audits. During the Term, Client’s Representatives shall be granted access upon at least 10 business days’ prior
notice, at reasonable times during regular business hours, to (A) the portion of the Facility where Catalent performs Processing,
(B) relevant personnel involved in Processing and (C) Processing records described in Section 9.2, in each case solely for the
purpose of verifying that Catalent is Processing in accordance with cGMPs, Applicable Laws, the Specifications and the Product
master Batch records. Client may not conduct an audit under this Section more than once during any 12 month period; provided, that
additional inspections may be conducted by or on behalf of Client as deemed appropriate by Client in the event there is a material
quality or compliance issue concerning Product or its Processing or to measure remediation following an audit by either Client
or a Regulatory Authority that resulted in a finding of deficiency. Client’s Quality Assurance Manager will arrange Client
audits with Catalent Quality Management. Audits shall be designed to minimize disruption of operations at the Facility. Client’s
Representatives who are not employees of Client shall be required to sign Catalent’s standard visitor confidentiality agreement
prior to being allowed access to the Facility. Such Representatives shall comply with the Facility’s rules and regulations
which are made known in advance to Client. Client shall indemnify and hold harmless Catalent for any action or activity of such
Representatives while on Catalent’s premises.

9.6       

Recall. If
a Regulatory Authority orders or requires the recall of any Product supplied hereunder or if either Catalent or Client believes
a recall, field alert, Product withdrawal or field correction (“Recall”) may be necessary with respect to any
Product supplied under this Agreement, the party receiving the notice from the Regulatory Authority or that holds such belief shall
promptly notify the other party in writing. With respect to any Recall, Catalent shall provide all necessary cooperation and assistance
to Client.  Client shall provide Catalent with an advance copy of any proposed submission to a Regulatory Authority in respect
of any Recall, and shall consider in good faith any comments from Catalent.  The cost of any Recall shall be borne by Client,
and Client shall reimburse Catalent for expenses incurred in connection with any Recall, in each case except to the extent such
Recall is caused by Catalent’s breach of its Processing obligations under this Agreement or Catalent’s violation of
Applicable Laws, then such cost shall be borne by Catalent in proportion to Catalent’s contribution to the cause of the Recall. 
For purposes hereof, such Catalent cost shall be limited to reasonable, actual and documented administrative costs incurred by
Client for such Recall and if applicable, replacement of the Product subject to Recall both in accordance with Article 5. 

9.7       

Quality Agreement.
Within 6 months after the Effective Date, and in any event prior to the first Processing of Product hereunder,
the parties shall negotiate in good faith and enter into a quality agreement on Catalent’s standard template or such other
template agreed to by the parties (the “Quality Agreement”). The Quality Agreement shall
in no way determine liability or financial responsibility of the parties for the responsibilities set forth therein. In the event
of a conflict between any of the provisions of this Agreement and the Quality Agreement with respect to quality-related activities,
including compliance with cGMP, the provisions of the Quality Agreement shall govern. In the event of a conflict between any of
the provisions of this Agreement and the Quality Agreement with respect to any commercial matters, including allocation of risk,
liability and financial responsibility, the provisions of this Agreement shall govern.

    	 	13	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

ARTICLE 10

CONFIDENTIALITY AND NON-USE

10.1       

Definition.
As used in this Agreement, the term “Confidential Information” includes all information furnished by or on behalf
of Catalent or Client, their respective Affiliates or any of its or their respective Representatives (the “Discloser”),
to the other party (the “Recipient”), its Affiliates or any of its or their respective Representatives, whether
furnished before, on or after the Effective Date and furnished in any form, including written, verbal, visual, electronic or in
any other media or manner and information acquired by observation or otherwise during any site visit at the other party’s
facility. Confidential Information includes all proprietary technologies, know-how, trade secrets, discoveries, inventions and
any other intellectual property (whether or not patented), analyses, data, regulatory submission Information, compilations, business
or technical information, strategies, or plan, samples, and other materials prepared or possessed by either party, their respective
Affiliates, or any of its or their respective Representatives, containing or based in whole or in part on any information furnished
by the Discloser, its Affiliates or any of its or their respective Representatives. Confidential Information also includes the
existence of this Agreement and its terms. The manufacturing process parameters which are being provided to Catalent from Client,
the Specifications and data resulting from performance of this Agreement by Catalent shall be considered Client’s Confidential
Information. Items and information for which ownership has been allocated to Client under the Development Agreement shall be deemed
to be the Confidential Information of Client under this Agreement.

10.2       

Exclusions.
Notwithstanding Section 10.1, Confidential Information does not include information that (A) is or becomes generally available
to the public or within the industry to which such information relates other than as a result of a breach of this Agreement, (B)
is already known by the Recipient at the time of disclosure as evidenced by the Recipient’s written records created in the
ordinary course of business, (C) becomes available to the Recipient on a non-confidential basis from a source that is entitled
to disclose it on a non-confidential basis or (D) was or is independently developed by or for the Recipient without reference to
the Confidential Information of the Discloser as evidenced by the Recipient’s contemporaneously created written records.

10.3       

Mutual Obligation.
The Recipient agrees that it will not use the Discloser’s Confidential Information except in connection with the performance
of its obligations or the exercise of its rights under this Agreement, and will not disclose, without the prior written consent
of the Discloser, Confidential Information of the Discloser to any third party, except that the Recipient may disclose the Discloser’s
Confidential Information to any of its Affiliates and its or their respective Representatives and subcontractors for which consent
has been given pursuant to Section 6.3 and who have obligations of confidentiality and non-use at least as rigorous as those terms
herein, in each case, that (A) need to know such Confidential Information for the purpose of performing under this Agreement, (B)
are advised of the contents of this Article and (C) are bound to the Recipient by obligations of confidentiality at least as restrictive
as the terms of this Article. Each party shall be responsible for any breach of this Article by its Affiliates or any of its or
their respective Representatives or any person receiving Confidential Information directly or indirectly from or through the Recipient.

10.4       

Permitted Disclosure.
The Recipient may disclose the Discloser’s Confidential Information to the extent required by law or regulation; provided,
that prior to making any such legally required disclosure, the Recipient shall give the Discloser as much prior notice of the requirement
for and contents of such disclosure as is practicable under the circumstances. Any such disclosure, however, shall not relieve
the Recipient of its obligations contained herein.

10.5       

No Implied License.
Except as expressly set forth in Section 10.1, the Recipient will obtain no right of any kind or license under any Confidential
Information of the Discloser, including any patent application or patent, by reason of this Agreement. All Confidential Information
will remain the sole property of the Discloser, subject to Article 11.

10.6       

Return of Confidential
Information. Upon expiration or termination of this Agreement, the Recipient will (and will cause its Affiliates and its and
their respective Representatives to) cease its use and, upon written request, within 30 days either return or destroy (and certify
as to such destruction) all Confidential Information of the Discloser, including any copies thereof, except for a single copy which
may be retained for the sole purpose of ensuring compliance with its continuing obligations under this Agreement.

    	 	14	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

10.7       

Survival.
The obligations of this Article will terminate with respect to items of Confidential Information upon the entry thereof into general
knowledge in the public domain, other than due to breach of this Agreement by the Recipient thereof or by a person receiving such
Confidential Information from or through the Recipient, but in no event earlier than five (5) years from the expiration or earlier
termination of this Agreement.

10.8       

Reverse Engineering.
Unless otherwise consented to by the Discloser in writing or provided for in a separate agreement between the parties, the Recipient
will not analyze for chemical composition any samples or materials that are the Confidential Information of Discloser, nor to allow
or cause any such samples or materials that are the Confidential Information of Discloser to be released to third parties for analysis;
provided, however, (i) this Section 10.8 shall not be construed to prevent Client from testing Product or items related to Product
itself or through third parties, as it sees fit in its sole and absolute discretion; and (ii) this Section 10.8 shall not be construed
to prevent Catalent from analyzing for chemical composition samples or materials that are commercially available or from developing
or manufacturing products containing Estradiol, including Generic Products so long as Catalent does not utilize Client’s
Confidential Information to do so.

ARTICLE 11

INTELLECTUAL PROPERTY

11.1       

The parties hereby
acknowledge that it is neither their intention nor the purpose of this Agreement to engage in inventive steps in the conception,
reduction to practice or development of intellectual property. Nevertheless, in the event, and to the extent, that intellectual
property is conceived, reduced to practice, developed or otherwise created by or on behalf of either or both of the parties in
connection with this Agreement, the ownership of such intellectual property shall be subject to the terms and conditions of Sections
7.1 and 7.2 of the Development Agreement, as if such intellectual property was conceived, reduced to practice or developed pursuant
to the Development Agreement.

11.2       

Transfer.
Following notice given by Client to Catalent, Catalent will provide reasonable assistance to effect the timely and orderly transfer
of the Process Know-How, and pertinent books and records (or copies thereof, as the case may be) pursuant to the Process Know-How
Transfer Plan to Client pursuant to this Section 11.2 and the Process Know-How Transfer Plan whether to establish a second source
during the term of this Agreement or at or about the time of termination or expiration of this Agreement. Catalent shall only be
obligated to use its commercially reasonable efforts in the implementation of the Process Know-How Transfer Plan, and in no case
shall Catalent personnel visit the site of Client or any third party manufacturer of softgels, as the case may be. For the avoidance
of doubt, the foregoing prohibition shall not be construed as a basis for Catalent refusing to assist in the transfer of analytical
methods to an independent laboratory, including a visit by Catalent personnel to such site to assist in method transfer, if, and
only as, reasonably necessary, and at Client’s cost and expense.

11.3       

Books and Records.
Where any document, or books and records contain Process Know-How together with other information of Catalent, its Affiliates or
their respective subcontractors, or other Catalent customers, Catalent shall only be required to provide to Client a copy of that
portion of that document or books and records that discloses the Process Know-How that pertains to the Product. When transferred
to Client, such copies will be the property of Client. Catalent may retain the original books and records and any documents required
by Applicable Laws to be retained by Catalent, which disclose the Process Know-How. After completion of performance of the Process
Know-How Transfer Plan, before destroying any documents, or books and records which contain material disclosures of Process Know-How
that have not been previously been provided to Client (whether in the same form or some other form), Catalent will notify Client
of such intended destruction and provide Client with thirty (30) days to notify Catalent in writing whether Client wishes to obtain
the same to the extent it is entitled to under this Agreement, in which case Catalent will deliver the requested document or books
and records (or copies of all or a portion thereof, as the case may be) to Client at Client’s sole cost and expense.

    	 	15	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

11.4       

Client Marks.
Catalent will not use Client’s Marks without prior written authorization from Client. The Marks are, and will remain, Client’s
sole and exclusive property, and Catalent has not acquired, and will not acquire (by operation of law, this Agreement, or otherwise),
any right, title, or interest in any of Client’s Marks other than as explicitly provided in writing by Client. Any and all
goodwill and rights that arise under trademark and copyright law, and all other intellectual property rights that arise in favor
of Client’s Marks as a result of this Agreement or otherwise, will inure to the sole and exclusive benefit of Client. Subject
to the next sentence, during the Term of this Agreement, Catalent will not attack, dispute, or challenge Client’s right,
title, and interest in and to Client’s Marks or assist others in so doing. Catalent reserves the right to attack, dispute,
or challenge Client’s right, title, and interest in and/or to Client’s Marks or assist others in so doing, if Catalent
believes in good faith that Client’s Mark infringes a Mark owned by or licensed to Catalent or one of its Affiliates.

11.5       

Analytical Methods.
Catalent, in the development of analytical methods for a Generic Product, whether on its own behalf or on behalf of a third party,
shall not use the services of any person, whether an employee or contractors, in the development of such methods, who either (i)
provided analytical method development services on behalf of Catalent under this Agreement or the Development Agreement, or (ii)
has such intimate knowledge of the Client’s analytical methods or the manner in which such methods were developed that such
persons participation in the development of the analytical method for a Generic Product could reasonably be determined to materially
accelerate the development of such methods for the Generic Product.  “Generic Product” shall mean [***].

 

ARTICLE 12

REPRESENTATIONS AND WARRANTIES AND
COMPLIANCE

12.1       

Catalent.
Catalent represents, warrants and undertakes to Client that:

A.       

at the time of delivery
by Catalent as provided in Section 6.1, Product shall have been Processed in accordance with this Agreement and with Applicable
Laws and in conformance with the Specifications and shall not be adulterated, misbranded or mislabeled within the meaning of Applicable
Laws; provided, that Catalent shall not be liable for defects attributable to Client-supplied Materials (including artwork,
advertising and labeling);

B.       

all personnel, employees,
and agents of Catalent and its Affiliates and their respective subcontractors who perform services, are and will continue to be
qualified and to have sufficient technical expertise to perform Catalent’s obligations under this Agreement;

C.       

Catalent has the full
power and authority to execute and deliver this Agreement and perform its covenants, duties, and obligations described in this
Agreement, and once executed, this Agreement will be a valid, legal, and binding obligation upon Catalent;

D.       

Catalent is not now,
nor will it be, a party to any agreement which would prevent Catalent from fulfilling its obligations under this Agreement, and
that during the Term of this Agreement will not enter into any agreement with any other party that would in any way prevent Catalent
from performing its obligations under this Agreement;

E.       

Catalent will maintain
all records and reports as required under this Agreement, and as required to comply with Applicable Laws;

F.       

Catalent will not in
the performance of its obligations under this Agreement use the services of any person debarred or suspended (or subject to debarment
or suspension) under 21 U.S.C. §335(a) or (b) or otherwise disqualified by Applicable Law;

    	 	16	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

G.       

(i) Catalent is not
nor has it ever been, and (ii) Catalent has not used, and will not use, the services of any person excluded, debarred, suspended,
or otherwise ineligible to participate in the Federal health care programs or in Federal procurement or non-procurement programs,
and has not used, and will not use, the services of any person listed on the HHS/OIG List of Excluded Individuals/Entities (http://www.oig.hhs.gov),
the GSA’s List of Parties Excluded from Federal Programs (http://www.epls.gov), or the FDA Debarment List (http://www.fda.gov/ora/compliance_ref/debar/default.htm),
as amended or replaced from time to time, in connection with any of the services performed under this Agreement. Catalent further
certifies that it, and any other person or entity used by Catalent in performing any of the services under this Agreement, has
not been convicted of a criminal offense that falls within the ambit of 42 U.S.C. §1320a-7(a). Catalent agrees to notify Client
promptly in the event Catalent, or any person used by Catalent in connection with this Agreement, ever becomes excluded, debarred,
suspended, or otherwise ineligible to participate in Federal health care programs or in Federal procurement or non-procurement
programs. This certification applies to Catalent and its respective officers, agents, and employees as well as subcontractors performing
on behalf of Catalent under this Agreement;

H.       

Catalent has all necessary
authority to use the Catalent technology utilized with the Product and as contemplated by this Agreement; there are no patents
owned by others related to the Catalent IP utilized with the Product that would be infringed or misused by Catalent’s performance
of the Agreement; and, to its knowledge, no trade secrets or other proprietary rights of others related to the Catalent IP utilized
with the Product that would be infringed or misused by Catalent’s performance of this Agreement;

I.       

Catalent will not release
any Batch of Product if the required certificates of conformance indicate that Product does not comply with the Specifications;
and

J.       

no transactions or
dealings under this Agreement shall be conducted with or for an individual or entity that is designated as the target of any sanctions,
restrictions or embargoes administered by the United Nations, European Union, United Kingdom, or the United States. 

12.2       

Client. Client
represents, warrants and undertakes to Catalent that:

A.       

all Client-supplied
Materials shall have been produced in accordance with Applicable Laws, shall comply with all applicable specifications, including
the Specifications, shall not be adulterated, misbranded or mislabeled within the meaning of Applicable Laws, and shall have been
provided in accordance with the terms and conditions of this Agreement;

B.       

the content of all
artwork provided to Catalent shall comply with all Applicable Laws;

C.       

all Product delivered
to Client by Catalent shall be held, used and disposed of by or on behalf of the Client in accordance with all Applicable Laws,
and Client will otherwise comply with all laws, rules, regulations and guidelines applicable to Client’s performance under
this Agreement;

D.       

Client will not release
any Batch of Product if the required certificates of conformance indicate that Product does not comply with the Specifications
or if Client does not hold all necessary Regulatory Approvals to market and sell the Product;

E.       

Client has all necessary
authority to use and to permit Catalent to use pursuant to this Agreement all intellectual property related to Product or Client-supplied
Materials (including artwork), and the Processing by Catalent of the foregoing, including any copyrights, trademarks, trade secrets,
patents, inventions and developments; to Client’s knowledge there are no patents owned by others related to the Client IP
utilized with the Product that would be infringed or misused by Client’s performance of the Agreement; and, to its knowledge,
no trade secrets or other proprietary rights of others related to the Client IP utilized with the Product that would be infringed
or misused by Client’s performance of this Agreement;

    	 	17	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

F.       

To Client’s knowledge
the services to be performed by Catalent under this Agreement will not violate or infringe upon any trademark, tradename, copyright,
patent, trade secret, or other intellectual property or other right held by any person or entity; provided that Client makes no
representation with respect to the Catalent IP;

G.       

Client has all authorizations
and permits required to deliver API (or have delivered) to Catalent’s Facility;

H.       

Client has the full
power and authority to execute and deliver this Agreement and perform its covenants, duties, and obligations described in this
Agreement, and once executed, this Agreement will be a valid, legal, and binding obligation upon Client; and

I.       

no transactions or
dealings under this Agreement shall be conducted with or for an individual or entity that is designated as the target of any sanctions,
restrictions or embargoes administered by the United Nations, European Union, United Kingdom, or the United States. 

12.3       

Limitations.
THE REPRESENTATIONS AND WARRANTIES SET FORTH IN THIS ARTICLE ARE THE SOLE AND EXCLUSIVE REPRESENTATIONS AND WARRANTIES MADE BY
EACH PARTY TO THE OTHER PARTY, AND NEITHER PARTY MAKES ANY OTHER REPRESENTATIONS, WARRANTIES OR GUARANTEES OF ANY KIND WHATSOEVER,
INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE.

 12.4

Compliance with Anti-Corruption
Laws.

Each party agrees
that, in the performance of its obligations under this Agreement, it will not: (i) provide or promise to provide, directly or
indirectly, any unlawful contribution, gift, entertainment, or other unlawful payment to any foreign or domestic government employee
relating to political activity; (ii) take any action, directly or indirectly, that violates Foreign Corrupt Practices Act (“FCPA”),
or any other applicable anti-corruption law of any foreign jurisdiction, including, without limitation, “use of the mails
or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay, or authorization
of the payment of any money, or offer, gift, promise to give, or authorization of the giving of anything of value” to any
“foreign official” (as is defined in the FCPA), any foreign political party or official thereof, or any candidate
for foreign political office, to influence their acts or decisions in their official capacity, to induce them to do or omit from
doing any act in violation of their lawful duty, or to secure any improper advantage in order to assist in obtaining business,
or retaining business, or directing business to any person; and (iii) make or propose to make any bribe, payoff, influence payment,
kickback, unlawful rebate, or other similar unlawful payment of any nature, including to healthcare providers or those employed
by any governmental institutions. 

ARTICLE 13

INDEMNIFICATION

13.1       

Indemnification
by Catalent. Catalent shall indemnify, defend and hold harmless Client, its Affiliates, and their respective shareholders,
directors, officers and employees (“Client Indemnitees”) from and against any and all suits, claims, losses,
demands, liabilities, damages, costs and expenses (including reasonable attorneys’ fees and reasonable investigative costs)
in connection with any suit, demand or action brought by any third party (“Losses”) directly or indirectly arising
out of or resulting from (a) any breach of its representations, warranties or obligations set forth in this Agreement; (b) any
negligence or willful misconduct by Catalent, its Affiliates, subcontractors, employees or agents; (c) any misrepresentation made
by Catalent in this Agreement; (d) a violation of, or non-compliance with any Applicable Law by Catalent, its Affiliates, subcontractors,
employees or agents in the performance of this Agreement; or (e) the infringement or alleged infringement of any trade secrets,
copyrights, trademarks, trade names, or other proprietary or contractual rights of any third party arising from Catalent’s
performance of services under this Agreement (except to the extent arising from the making or using of Client-supplied Materials,
Client Confidential Information, or API), in each case of clauses (a) through (e) above, except to the extent that Client is obligated
to indemnify any of the Catalent Indemnitees pursuant to Section 13.2 for such events.

    	 	18	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

13.2       

Indemnification
by Client. Client shall indemnify, defend and hold harmless Catalent, its Affiliates, and their respective shareholders, directors,
officers and employees (“Catalent Indemnitees”) from and against any and all Losses directly or indirectly arising
out of or resulting from (a) any manufacture (other than due to negligence by or on behalf of Catalent), packaging (other than
due to negligence by or on behalf of Catalent), promotion, distribution, sale or use of or exposure to the Product or Client-supplied
Materials, including API and including product liability or strict liability, other than claims by Catalent employees arising from
their handling of Client-supplied Materials in performing the services under this Agreement; provided, however, Client delivered
to Catalent all known material information regarding such risks of handling or such information was otherwise in the public domain;
(b) any negligence or willful misconduct of Client, its Affiliates, subcontractors, employees or agents, (c) any breach of its
representations, warranties or obligations set forth in this Agreement; (d) the content of Client’s instructions to the extent
they are followed by Catalent and violate Applicable Laws; (e) the conduct of any clinical trials utilizing Product or API; (f)
Client’s exercise of control over the Processing, to the extent that Client’s instructions or directions violate Applicable
Laws, (g) any actual or alleged infringement or violation of any third party patent, trade secret, copyright, trademark or other
proprietary right by the use, as authorized, of intellectual property or other information provided by Client to Catalent, including
Client-supplied Material; in each case of clauses (a) through (g) above, except to the extent that Catalent is obligated to indemnify
any of the Client Indemnitees pursuant to Section 13.1 for such events.

13.3       

Indemnification
Procedures. All indemnification obligations in this Agreement are conditioned upon the indemnified party (a) promptly notifying
the indemnifying party of any claim or liability of which the indemnified party becomes aware (including a copy of any related
complaint, summons, notice or other instrument); provided, that failure to provide such notice within a reasonable period of time
shall not relieve the indemnifying party of any of its obligations hereunder except to the extent the indemnifying party is prejudiced
by such failure, (b) allowing the indemnifying party to conduct and control the defense of any such claim or liability and any
related settlement negotiations (at the indemnifying party’s expense), (C) cooperating with the indemnifying party in the
defense of any such claim or liability and any related settlement negotiations (at the indemnifying party’s expense) and
(D) not compromising or settling any claim or liability without prior written consent of the indemnifying party.

ARTICLE 14

LIMITATIONS OF LIABILITY

14.1       

CATALENT’S
LIABILITY UNDER THIS AGREEMENT FOR ANY AND ALL CLAIMS FOR LOST, DAMAGED OR DESTROYED CLIENT-SUPPLIED MATERIALS, WHETHER OR NOT
SUCH CLIENT SUPPLIED MATERIALS ARE USED IN THE SERVICES OR INCORPORATED INTO PRODUCT, CAUSED BY CATALENT’S NEGLIGENCE OR
BREACH SHALL NOT EXCEED [***] PER INCIDENT.

14.2       

CATALENT’S
TOTAL LIABILITY UNDER THIS AGREEMENT SHALL IN NO EVENT EXCEED THE TOTAL FEES PAID BY CLIENT TO CATALENT OR INVOICED BY CATALENT
UNDER THIS AGREEMENT DURING THE TWELVE (12) MONTHS PRECEDING RELEASE OF THE BATCH OR SERVICES GIVING RISE TO THE CLAIM. DURING
THE FIRST CONTRACT YEAR, SUCH LIMITATION SHALL BE THE GREATER OF (I) TOTAL FEES PAID BY CLIENT TO CATALENT OR INVOICED BY CATALENT
FROM THE COMMENCEMENT DATE, OR (II) [***]. THE FOREGOING LIMITATION SHALL NOT BE DEEMED TO LIMIT CATALENT’S LIABILITY UNDER
SECTION 13.1 (INDEMNIFICATION) WITH RESPECT TO AMOUNTS PAID BY CLIENT TO THIRD PARTIES FOR BODILY INJURY.

14.3       

NEITHER PARTY SHALL
BE LIABLE TO THE OTHER PARTY FOR INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OR LOSS OF REVENUES, PROFITS
OR DATA ARISING OUT OF PERFORMANCE UNDER THIS AGREEMENT, WHETHER IN CONTRACT OR IN TORT, EVEN IF SUCH PARTY HAS BEEN ADVISED OF
THE POSSIBILITY OF SUCH DAMAGES.

    	 	19	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

ARTICLE 15

INSURANCE

15.1       

Each of Catalent
and Client shall, at its own cost and expense, obtain and maintain in full force and effect during the Term the following: (A)
Commercial General Liability Insurance with a per-occurrence limit of not less than $[***]; (B) Products and Completed Operations
Liability Insurance with a per-occurrence limit of not less than $[***]; (C) Workers’ Compensation Insurance with statutory
limits and Employers Liability Insurance with limits of not less than $[***] per accident; and (D) All Risk Property Insurance,
including transit coverage, in an amount equal to the full replacement value of its property while in, or in transit to, a Catalent
facility as required under this Agreement. Each party may self-insure all or any portion of the required insurance as long as,
together with its Affiliates, its US GAAP net worth is greater than $[***] million or its annual EBITDA (earnings before interest,
taxes, depreciation and amortization) is greater than $[***] million. If any of the required policies of insurance are written
on a claims made basis, such policies shall be maintained throughout the Term and for a period of at least [***] years thereafter.
Each required insurance policy, other than self-insurance, shall be obtained from an insurance carrier with an A.M. Best rating
of at least A- VII. To secure the performance of its obligations under this Agreement, Client will at all times during the Term
of this Agreement, maintain commercial general liability insurance providing coverage of no less than $[***] per occurrence, professional
liability insurance providing coverage of no less than $[***] per occurrence, errors and omissions insurance providing coverage
of no less than $[***] per occurrence and Workers’ Compensation Insurance with statutory amounts and Employers Liability
Insurance with limits of not less than $[***] per accident; and Auto Liability insurance for owned, hired and non-owned vehicles
in a minimum amount of $[***] combined single limit. If requested by the other party, the party will furnish certificates of insurance
evidencing such coverages or the original of the insurance policies. No such policies required hereunder will be cancelable or
subject to reduction of coverage or other modification except after [***] days’ prior written notice to the other party.

ARTICLE 16

TERM AND TERMINATION

16.1       

Term. This
Agreement shall commence on the Effective Date and shall continue until the end of the seventh Contract Year, unless earlier terminated
in accordance with Section 16.2 (as may be extended in accordance with this Section, the “Term”). The Term shall
automatically be extended for successive 2-year periods unless and until one party gives the other party at least 12 months’
prior written notice of its desire to terminate as of the end of the then-current Term.

16.2       

Termination.
This Agreement may be terminated immediately without further action:

A.       

by either party if
the other party files a petition in bankruptcy, or enters into an agreement with its creditors, or applies for or consents to the
appointment of a receiver, administrative receiver, trustee or administrator, or makes an assignment for the benefit of creditors,
or suffers or permits the entry of any order adjudicating it to be bankrupt or insolvent and such order is not discharged within
30 days, or takes any equivalent or similar action in consequence of debt in any jurisdiction; or

B.       

by either party if
the other party materially breaches any of the provisions of this Agreement and such breach is not cured within 60 days after the
giving of written notice requiring the breach to be remedied; provided, that in the case of a failure of Client to make
payments in accordance with the terms of this Agreement, Catalent may terminate this Agreement if such payment breach is not cured
within 30 days of receipt of notice of non-payment from Catalent.

C.       

By Client upon one
hundred eighty (180) days prior written notice to Catalent in the event Client ceases pursuit of Regulatory Approval for, or to
offer for sale or to sell, Product, due to material regulatory, patient health, or intellectual property issues.

    	 	20	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

16.3       

Effect of Termination.
Expiration or termination of this Agreement shall be without prejudice to any rights or obligations that accrued to the benefit
of either party prior to such expiration or termination. In the event of a termination of this Agreement:

A.       

Catalent shall promptly
return to Client, at Client’s expense and direction, any remaining inventory of Product or Client-supplied Materials; provided,
that all outstanding invoices have been paid in full;

B.       

Client shall pay Catalent
all invoiced amounts outstanding hereunder, plus, upon receipt of invoice therefor, for any (i) Product that has been shipped pursuant
to Purchase Orders but not yet invoiced, (ii) Product Processed pursuant to Purchase Orders that has been completed but not yet
shipped, and (iii) in the event that this Agreement is terminated for any reason other than by Client pursuant to Section 16.2(A)
or (B), or by Catalent pursuant to Section 16.2(C), all Product in process of being Processed pursuant to Purchase Orders (or,
alternatively, Client may instruct Catalent to complete such work in process, and the resulting completed Product shall be governed
by clause (ii)); and

C.       

in the event that this
Agreement is terminated for any reason other than by Client pursuant to Section 16.2(A) or (B), or by Catalent pursuant to Section
16.2(C), Client shall pay Catalent for all costs and expenses incurred, and all noncancellable commitments made, in connection
with Catalent’s performance of this Agreement, so long as such costs, expenses or commitments were made by Catalent consistent
with Client’s most recent Firm Commitment and the vendor’s minimum purchase obligations.

16.4       

Survival.
The rights and obligations of the parties shall continue under Articles 11 (Intellectual Property), 13 (Indemnification), 14 (Limitations
of Liability), 17 (Notice), 18 (Miscellaneous); under Articles 10 (Confidentiality and Non-Use) and 15 (Insurance), in each case
to the extent expressly stated therein; and under Sections 7.3 (Payment Terms), 7.5 (Taxes), 7.6 (Client and Third Party Expenses),
9.1 (Recordkeeping), 9.6 (Recall), 12.3 (Limitations on Warranties), 16.3 (Effect of Termination) and 16.4 (Survival), in each
case in accordance with their respective terms if applicable, notwithstanding expiration or termination of this Agreement.

ARTICLE 17

NOTICE

All notices and other communications
hereunder shall be in writing and shall be deemed given: (A) when delivered personally or by hand; (B) when delivered by facsimile
transmission (receipt verified); (C) when received or refused, if sent by registered or certified mail (return receipt requested),
postage prepaid; or (D) when delivered, if sent by express courier service; in each case to the parties at the following addresses
(or at such other address for a party as shall be specified by like notice; provided, that notices of a change of address
shall be effective only upon receipt thereof):

 

	To Client:	TherapeuticsMD, Inc.
	 	6800 Broken Sound Parkway NW, Third Floor
	 	Boca Raton, Florida 33487
	 	Attn:  President
	With a copy to:	Chief Legal Counsel at the above address
	 	 
	To Catalent:	Catalent Pharma Solutions, LLC
	 	2725 Scherer Drive N.
	 	St. Petersburg, FL 33716
	 	Attn: President, Softgel
	 	 
	With a copy to:	Catalent Pharma Solutions
	 	14 Schoolhouse Road
	 	Somerset, NJ  08873
	 	Attn: General Counsel (Legal Department)
	 	Facsimile: +1 (732) 537-6491

 

    	 	21	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

ARTICLE 18

MISCELLANEOUS

18.1       

Entire Agreement;
Amendments. This Agreement, together with the Quality Agreement, constitutes the entire understanding between the parties,
and supersedes any contracts, agreements or understandings (oral or written) of the parties, with respect to the subject matter
hereof. For the avoidance of doubt, this Agreement does not supersede any existing generally applicable confidentiality agreement
between the parties as it relates to time periods prior to the date hereof or to business dealings not covered by this Agreement.
No term of this Agreement may be amended except upon written agreement of both parties, unless otherwise expressly provided in
this Agreement.

18.2       

Captions; Certain
Conventions. The captions in this Agreement are for convenience only and are not to be interpreted or construed as a substantive
part of this Agreement. Unless otherwise expressly provided herein or the context of this Agreement otherwise requires, (A) words
of any gender include each other gender, (B) words such as “herein”, “hereof”, and “hereunder”
refer to this Agreement as a whole and not merely to the particular provision in which such words appear, (C) words using the singular
shall include the plural, and vice versa, (D) the words “include(s)” and “including” shall be deemed to
be followed by the phrase “but not limited to”, “without limitation” or words of similar import, (E) the
word “or” shall be deemed to include the word “and” (e.g., “and/or”) and (F) references to
“Article,” “Section,” “subsection,” “clause” or other subdivision, or to an Attachment
or other appendix, without reference to a document are to the specified provision or Attachment of this Agreement. This Agreement
shall be construed as if it were drafted jointly by the parties.

18.3       

Further Assurances.
The parties agree to execute, acknowledge and deliver such further instruments and to take all such other incidental acts as may
be reasonably necessary or appropriate to carry out the purpose and intent of this Agreement.

18.4       

No Waiver.
Failure by either party to insist upon strict compliance with any term of this Agreement in any one or more instances will not
be deemed to be a waiver of its rights to insist upon such strict compliance with respect to any subsequent failure.

18.5       

Severability.
If any term of this Agreement is declared invalid or unenforceable by a court or other body of competent jurisdiction, the remaining
terms of this Agreement will continue in full force and effect.

18.6       

Independent Contractors.
The relationship of the parties is that of independent contractors, and neither party will incur any debts or make any commitments
for the other party except to the extent expressly provided in this Agreement. Nothing in this Agreement is intended to create
or will be construed as creating between the parties the relationship of joint ventures, co-partners, employer/employee or principal
and agent. Neither party shall have any responsibility for the hiring, termination or compensation of the other party’s employees
or contractors or for any employee benefits of any such employee or contractor.

18.7       

Successors and
Assigns. This Agreement will be binding upon and inure to the benefit of the parties, their successors and permitted assigns.
Neither party may assign this Agreement, in whole or in part, without the prior written consent of the other party, except that
either party may, without the other party’s consent (but subject to prior written notice), assign this Agreement in its entirety
to an Affiliate or to a successor to substantially all of the business or assets of the assigning party or the assigning party’s
business unit responsible for performance under this Agreement.

18.8       

No Third Party
Beneficiaries. This Agreement shall not confer any rights or remedies upon any person or entity other than the parties named
herein and their respective successors and permitted assigns.

18.9       

Governing Law.
This Agreement shall be governed by and construed under the laws of the State of Delaware, USA, excluding its conflicts of law
provisions. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement.

    	 	22	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

18.10       

Dispute Resolution.
Any dispute that arises between the parties in connection with this Agreement shall first be presented to the senior executives
of the parties for consideration and resolution. If such executives cannot reach a resolution of the dispute within a reasonable
time, then the parties may seek remedies in a court of law.

18.11       

Prevailing Party.
In any dispute resolution proceeding between the parties in connection with this Agreement, the prevailing party may be entitled
to recover its reasonable attorney’s fees and costs in such proceeding from the other party.

18.12       

Publicity.
Neither party will make any press release or other public disclosure regarding this Agreement or the transactions contemplated
hereby without the other party’s express prior written consent, except as required under Applicable Laws, by any governmental
agency or by the rules of any stock exchange on which the securities of the disclosing party are listed, in which case the party
required to make the press release or public disclosure shall use commercially reasonable efforts to obtain the approval of the
other party as to the form, nature and extent of the press release or public disclosure prior to issuing the press release or making
the public disclosure.

18.13       

Right to Dispose
and Settle. If Catalent requests in writing from Client direction with respect to disposal of any inventories of Product, Client-supplied
Materials, equipment, samples or other items belonging to Client and is unable to obtain a response from Client within a reasonable
time period after making reasonable efforts to do so, Catalent shall be entitled in its sole discretion to (A) dispose of all such
items and (B) set-off any and all amounts due to Catalent or any of its Affiliates from Client against any credits Client may hold
with Catalent or any of its Affiliates.

18.14       

Force Majeure.
Except as to payments required under this Agreement, neither party shall be liable in damages for, nor shall this Agreement be
terminable or cancelable by reason of, any delay or default in such party’s performance hereunder if such default or delay
is caused by events beyond such party’s reasonable control, including acts of God, law or regulation or other action or failure
to act of any government or agency thereof, war or insurrection, civil commotion, destruction of production facilities or materials
by earthquake, fire, flood or weather, labor disturbances, epidemic or failure of suppliers, vendors, public utilities or common
carriers; provided, that the party seeking relief under this Section shall immediately notify the other party of such cause(s)
beyond such party’s reasonable control. The party that may invoke this Section shall use commercially reasonable efforts
to reinstate its ongoing obligations to the other party as soon as practicable. If the cause(s) shall continue unabated for 180
days, then both parties shall meet to discuss and negotiate in good faith what modifications to this Agreement should result from
such cause(s).

18.15       

Counterparts.
This Agreement may be executed in one or more counterparts, each of which will be deemed an original but all of which together
will constitute one and the same instrument. Any photocopy, facsimile or electronic reproduction of the executed Agreement shall
constitute an original.

[Signature page follows]

    	 	23	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

    

 

IN WITNESS WHEREOF, the parties
have caused their respective duly authorized Representatives to execute this Agreement effective as of the Effective Date.

CATALENT
PHARMA SOLUTIONS, LLC THERAPEUTICSMD, INC.

 

	By:	/s/Aris Gennadios	 	By: 	/s/ Robert Finizio
	 	 	 
	Name: Aris Gennadios, Ph.D.	 	Name:  Robert Finizio
	 	 	 
	Title: President Softget Technology	 	Title:  CEO

 

 

 

Signature Page to Softgel Commercial Supply
Agreement

 

    	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

ATTACHMENT A

 

SPECIFICATIONS

 

 

I.        Client-supplied
Materials (and associated specifications)

 

		●	API

 

	Test	Acceptance Criteria	Analytical Method
	Appearance 	[***]	[***]
	Identification A (IR)	[***]	[***]
	Identification B (UV)	[***]	[***]
	Melting range	[***]	[***]
	Specific rotation	[***]	[***]
	Water 	[***]	[***]
	
        Assay (HPLC)

         
	[***]	[***]
	
        Microbial limits

         

        Total aerobic microbial count (TAMC):
	
         

         

        [***]
	[***]
	Total combined yeasts and mold count (TYMC):	[***]
	Escherichia in 1 g	[***]
	
        Related substances (HPLC):

         

        Estrone (Ph.Eur.A)
	
         

        [***]
	[***]
	17α-estradiol (Ph.Eur.B)	[***]
	Δ9(11)-estradiol (Ph.Eur.D)	[***]

 

    	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

	Test	Acceptance Criteria	Analytical Method
	4-Cl-estradiol	[***]	 
	Individual unspecified impurity	[***]
	Total impurities	[***]
	
        Residual Solvents (GC):

         

        Benzene
	[***]	
        [***]1

         

	Dichloromethane	[***]
	Ethanol	[***]
	Ethyl acetate	[***]
	Methanol	[***]
	Pyridine	[***]
	Tetrachloroethylene	[***]
	Acetic acid	[***]
	
         

        Particle size by laser diffraction

         
	[***]	[***]2

1 [***]

2 [***]

[***]

HPLC = high performance liquid chromatography

UV = ultraviolet

IR = infrared

GC = gas chromatograph

Ph. Eur. or EP = European Pharmacopeia

USP = United States Pharmacopeia

cfu = colony forming unit

ppm = parts per million

 

 

    	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

II.       

Product Specifications 

 

DRAFT SPECIFICATIONS – final to be agreed to in writing by
the parties after execution of this Agreement.

 

 

Estradiol 4 μg

 

	Test	Method 	Limits
	Appearance	[***]	[***]
	Estradiol Assay (4 μg/capsule)	[***]	[***]
	Related Compounds (Tested at RTP)	[***]	[***]
	[***]
	[***]
	[***]
	[***]
	Dissolution	[***]	[***]
	[***]
	[***]
	[***]
	Moisture Content	[***]	[***]
	Total Aerobic Plate Count	[***]	[***]
	Total Combined Yeast and Mold 	[***]	[***]
	P. aeruginosa	[***]	[***]
	S. aureus	[***]	[***]
	Candida albicans	[***]	[***]

  

 

    	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

Estradiol 10 μg

 

	Test	Method 	Limits
	Appearance	[***]	[***]
	Estradiol Assay (10 μg/capsule)	[***]	[***]
	Related Compounds (Tested at RTP)	[***]	[***]
	[***]
	[***]
	[***]
	[***]
	Dissolution	[***]	[***]
	[***]
	[***]
	[***]
	Moisture Content	[***]	[***]
	Total Aerobic Plate Count	[***]	[***]
	Total Combined Yeast and Mold 	[***]	[***]
	P. aeruginosa	[***]	[***]
	S. aureus	[***]	[***]
	Candida albicans	[***]	[***]

 

 

    	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

Estradiol 25 μg

 

	Test	Method 	Limits
	Appearance	[***]	[***]
	Estradiol Assay (25 μg/capsule)	[***]	[***]
	Related Compounds (Tested at RTP)	[***]	[***]
	[***]
	[***]
	[***]
	[***]
	Dissolution	[***]	[***]
	[***]
	[***]
	[***]
	Moisture Content	[***]	[***]
	Total Aerobic Plate Count	[***]	[***]
	Total Combined Yeast and Mold 	[***]	[***]
	P. aeruginosa	[***]	[***]
	S. aureus	[***]	[***]
	Candida albicans	[***]	[***]

 

 

    	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED AS [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
EXECUTION VERSION

    

 

ATTACHMENT B

 

UNIT PRICING, FEES AND MINIMUM REQUIREMENT

 

	UNIT PRICING-  Theoretical Batch Size of [***] softgels per strength
	Any Volume- Lot size to be phased out after first Contract Year based on validation of larger batch size
	Product	Unit Strength	Initial Unit Price
	Softgel Ovule	Estradiol 25 mcg	$[***]
	Softgel Ovule	Estradiol 10 mcg	$[***]
	Softgel Ovule	Estradiol 4 mcg	$[***]

 

 

	UNIT PRICING-  Theoretical Batch Size of 1,200,000 softgels per strength
	Tier 1 Volume: [***] Total Softgels Shipped in Calendar Year
	Product	Unit Strength	Initial Unit Price
	Softgel Ovule	Estradiol 25 mcg	$[***]
	Softgel Ovule	Estradiol 10 mcg	$[***]
	Softgel Ovule	Estradiol 4 mcg	$[***]
	Tier 2 Volume: Over [***] Total Softgels Shipped in Calendar Year
	Product	Unit Strength	Initial Unit Price For All Incremental Volume Over [***]
	Softgel Ovule	Estradiol 25 mcg	$[***]
	Softgel Ovule	Estradiol 10 mcg	$[***]
	Softgel Ovule	Estradiol 4 mcg	$[***]

 

* One unit is [***] softgel capsules. Prices
include full API release testing, cost of Processed softgels, Product full release testing and bulk packaging. Prices do not include
cost of API, tooling or other Product-specific capital items, artwork, shipping, insurance or duty. Prices also do not include
any testing, retesting or testing supplies other than as expressly set forth in the Specifications. Prices are based on certain
assumptions as to manufacturing processes, storage conditions, etc. Accordingly, prices are subject to adjustment in the event
any such assumptions are subject to revision in connection with the validation of the Product. The foregoing prices are for the
United States only. Prices will be adjusted for the Processing of Product for use in other jurisdictions based upon actual differences
in cost resulting from the intended use of Product in countries other than the United States.

 

	MINIMUM REQUIREMENT
	Contract Year	Product 	Minimum Requirement*
	[***]	Across all three strengths	[***] Softgels
	[***]	Across all three strengths	[***] Softgels
	[***]	Across all three strengths	[***] Softgels
	[***]	Across all three strengths	[***] Softgels
	[***]	Across all three strengths	[***] Softgels
	[***]	Across all three strengths	[***] Softgels

 

		*	Softgels shipped per Contract Year qualify towards the Minimum Requirement.

 

 

	ADDITIONAL FEES
	Type of Fee	Amount	Payable
	Product Maintenance Fee	$[***] for the first strength; $[***] for each additional strength 	
        [***]

         

         

	Hormone Suite Occupancy Fee	Waived based on minimum volume guarantees	N/A

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]